- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04874441
Candida PCR Diagnosis Strategy in Patients From Intensive Care Units (CANDI-PCR)
Evaluation of the Effect of the Implementation of a Candida PCR Diagnosis Strategy on the Time Required to Obtain Results in Patients From Intensive Care Units With Suspected Systemic Invasive Candidiasis: Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Invasive candidiasis is a serious infection caused by yeasts of the genus Candida sp. Their incidence is increasing, particularly in intensive care. The prognosis is severe and depends on the early initiation of adequate antifungal treatment. At present, the diagnosis of invasive candidiasis is difficult since blood culture, the reference technique, has major limitations due to its low sensitivity, as well as very long delays in obtaining results. As a consequence, suspected invasive candidiasis is often treated empirically with echinocandins, resulting in the development of resistance and extremely high costs for health care facilities. The switch to treatments such as fluconazole is often delayed, although this molecule is effective on most Candida species except C. krusei and glabrata and is much less expensive than echinocandins.
For these reasons, the present study developed faster and more efficient methods to diagnose Candida krusei and glabrata species, based on the detection of DNA in the blood by PCR, allowing an earlier switch from echinocandins to Fluconazole.
The patients included will be divided into 2 groups: one group of patients will benefit from a diagnostic strategy based on blood culture (reference technique for the detection of Candida) and another group of patients will benefit from a diagnostic strategy based on this new PCR technique. The main objective will be to evaluate the effect of the PCR strategy on the time to obtain results and on the switch of antifungal agents. After inclusion, patients will be followed up at day 14, day 28 until discharge (or 3 months if the patient is still hospitalised).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pamela CHAUVIN
- Phone Number: 05 67 69 04 09
- Email: chauvin.p@chu-toulouse.fr
Study Contact Backup
- Name: Xavier IRIART
- Phone Number: 05 67 69 04 99
- Email: iriart.x@chu-toulouse.fr
Study Locations
-
-
Occitanie
-
Toulouse, Occitanie, France, 31000
- Recruiting
- Uh Toulouse
-
Contact:
- PAMELA CHAUVIN, MD
- Email: CHAUVIN.P@CHU-TOULOUSE.FR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient affiliated or benefiting from a social protection system
- Patient (or his/her trusted person) having given free and informed written consent to the investigating physician
- Non-neutropenic patient hospitalised in the Toulouse University Hospital intensive care unit.
- Patient with suspected invasive candidiasis for whom a blood culture for fungal infection diagnosis was taken and for whom an empirical treatment with echinocandin at an adapted dose was implemented.
Exclusion Criteria:
- Patients under guardianship or trusteeship, persons under court protection
- Pregnant or breastfeeding patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: blood culture-based diagnostic strategy
Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy
|
|
Experimental: C. glabrata / krusei PCR diagnostic strategy
Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata / krusei PCR
|
For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reporting delay
Time Frame: 14 days after blood sample taken
|
the time (in hours) required for the results to be returned in relation to the time of sample collection
|
14 days after blood sample taken
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mortality at Day 28
Time Frame: 28 days after blood sample taken
|
Mortality rates will be taken 28 days after taking blood samples for Candida diagnosis in both groups
|
28 days after blood sample taken
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pamela CHAUVIN, MD, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RC31/19/0507
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Candida
-
Astellas Pharma IncCompleted
-
Outcome ReaAssistance Publique - Hôpitaux de ParisCompletedCandida InfectionsFrance
-
BayerSATO PHARMACEUTICAL , Ltd.Completed
-
Chinese PLA General HospitalUnknownTo Evaluate the Diagnostic Value of Candida Antigen Antibody Detection for Candida InfectionChina
-
CanXidaCitruslabsActive, not recruitingCandida Infection | Candida Albicans Infection | Candida SystemicUnited States
-
Medical University of ViennaCompletedCandida SepsisAustria
-
Ali ibrahim mahmoud shamardalUnknownEffect of Tio2 Nanoparticles on Candida Aggregation
-
Hams Hamed AbdelrahmanActive, not recruiting
-
University of PittsburghPfizerCompletedInfection | Candida | Non Albicans SpeciesUnited States
-
Cairo UniversityUnknown
Clinical Trials on Diagnosis strategy based on C. glabrata / krusei PCR
-
University Hospital, LilleRecruitingAspiration PneumoniaFrance